|
Optical Spectroscopy for Management of Cancer Treatment
Irving Bigio, Ph.D., Principle Investigator
bigio@bu.edu
Boston University
Grant Number: 1U54CA104677-01
Participating Organizations
- Academic: Boston University, University College of London, University of Pittsburgh
- Industrial: Optimum Technologies, Chemical Operations (Pharmacyclics), DiametRx, Inc
Modalities
In vivo contact probe for Elastic Scattering Spectroscopy and "Optical Pharmacokinetics" (fast UV through IR analytical in vivo spectrophotometry).
Clinical Impact
This innovative modality delivers analytical (absolute value) photometric spectra from 300 to 1000 nm (UV to IR) from the volume of interest. This break-through development delivers 3 analytical spectral readings per second, enabling site-specific tracking of absolute values for pharmacokinetics of bolus-administered drug, optical agent, and biochemical changes in vivo. It can be readily stepped to new spots to sample differences due to tumor heterogeneity. Its rapid data rate permits dynamic tracking of drug accumulation, conversion and/or washout (pharmacokinetics and aspects of pharmacodynamics) as well as permit microvasculature permeability analyses for assessment of angiogenesis, and prompt and longer term effects of anti-angiogenesis therapy. Elastic Scattering Spectroscopy measures rapid and slow changes in tissue granularity (cell organelles), suitable to measure and track changes in nuclear density, structure and condition before, during and after therapy - potentially an important clinical management tool.
Strengths
Their approach brings some better features of bench-style analytical biochemistry and pharmacokinetics to the real-time in vivo environment. It should be able to see disseminated clinical applications by the end of 5 years. The probes can be adapted to endoscopy and laparoscopy.
Synergisms with Other Teams
Both analytical and elastic scattering spectroscopy can correlate with data from fluorescence, diffusion and scattering spectroscopy that are important features of the other Teams. The other teams can use the powers of this method for analytical validations of their approaches to in vivo measurements, e.g.,
(1) optical imaging of neo-adjuvant therapy and other approaches to breast cancer treatment in the 5 participating NCI Comprehensive Cancer Centers of the first NTROI team;
(2) lymphatic spread, nodal metastases, non-invasive imaging of angiogenesis, correlates to hypoxia, hypoglycemia, blood flow, and markers for therapeutic response and toxicity - foci of colon cancer studies by the third NTROI team.
< Previous | Next Section > Main |
